

NOAT II Beneficiary Abatement Use Report

[per Section 2.6 NOAT II Agreement and Section 7 NOAT II TDP]

[1] Period Covered by Report: [1/1/2025](#) to [12/31/2025](#)

[2] Beneficiary Name: [Pennsylvania](#)

[3] Beneficiary Identifies as: [SAA State](#)

[4] NOAT II Abatement Distributions Received by the Beneficiary: [See Attachment 1](#)

[5] Total NOAT II Abatement Distributions Received by the Beneficiary (Across All Funding Cycles): [\\$ 15,278,845.71](#)

[6] Did the Beneficiary Disburse NOAT II Abatement Distributions during the Covered Period ? [Yes](#)

[7] Total Amount of NOAT II Abatement Distributions Disbursed during the Covered Period on Approved Abatement Use Categories: [\\$ 13,087,445.85](#)

[7a] Percentage of NOAT II Abatement Distributions Disbursed during the Covered Period on Approved Administrative Expenses: [0 %](#)

[8] Percentage of Total Abatement Distributions Disbursed during the Covered Period, by Abatement Use Category: [See Attachment 2](#)

[9] Authorized Person Completing this Report: [Briana Anderson, Administrator@paopioidtrust.org](#)

[10] Authorized NOAT II Point of Contact: [Briana Anderson, Opioid Trust Administrative Director](#)

[11] The information submitted in this report is provided by the Beneficiary identified above in accordance with the NOAT II governing documents: [Yes](#)

Attachment 1:

NOAT II Abatement Distributions Received by the Beneficiary

Beneficiary	NOAT II Funding Cycle	Reference #	Disbursement Date	Disbursement Amount	Payment Method	Confirm
<i>Pennsylvania</i>	<i>1st</i>	<i>Not assigned (Book transfer)</i>	<i>2023-01-31 00:00:00</i>	<i>\$ 7,020,010</i>	<i>Wire</i>	<i>X</i>
<i>Pennsylvania</i>	<i>2nd</i>	<i>none, internal transfer</i>	<i>2023-11-09 00:00:00</i>	<i>\$ 8,258,836</i>	<i>Wire</i>	<i>X</i>

Attachment 2:

Percentage of Total Abatement Distributions Disbursed during the Covered Period,

by Abatement Use Category [Pennsylvania]

Month / Year	% of NOAT II Abatement Distribution Disbursed	Approved Opioid Abatement Use Category	Approved Opioid Abatement Use Subcategory	Core Strategy
Jan-Jun 2025	3.05 %	H. Prevent Overdose Deaths and Other Harms (Harm Reduction)	Not Selected	A. NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES
Jan-Jun 2025	11.64 %	A. Treat Opioid Use Disorder (OUD)	Not Selected	B. MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT
Jan-Jun 2025	2.00 %	E. Address The Needs of Pregnant Or Parenting Women And Their Families, Including Babies With Neonatal Abstinence Syndrome	Not Selected	C. PREGNANT & POSTPARTUM WOMEN
Jan-Jun 2025	0.19 %	E. Address The Needs of Pregnant Or Parenting Women And Their Families, Including Babies With Neonatal Abstinence Syndrome	Not Selected	D. EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME
Jan-Jun 2025	5.90 %	C. Connect People Who Need Help to The Help They Need (Connections to Care)	Not Selected	E. EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES
Jan-Jun 2025	5.95 %	D. Address The Needs of Criminal-Justice-Involved Persons	Not Selected	F. TREATMENT FOR INCARCERATED POPULATION
Jan-Jun 2025	3.40 %	G. Prevent Misuse of Opioids	Not Selected	G. PREVENTION PROGRAMS
Jan-Jun 2025	0.02 %	L. Research	Not Selected	I. EVIDENCE-BASED DATA COLLECTION AND RESEARCH ANALYZING THE EFFECTIVENESS OF THE ABATEMENT STRATEGIES WITHIN THE STATE
Jan-Jun 2025	15.00 %	A. Treat Opioid Use Disorder (OUD)	Not Selected	Not Selected

Month / Year	% of NOAT II Abatement Distribution Disbursed	Approved Opioid Abatement Use Category	Approved Opioid Abatement Use Subcategory	Core Strategy
<i>Jan-Jun 2025</i>	<i>21.05 %</i>	<i>B. Support People in Treatment and Recovery</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>13.23 %</i>	<i>C. Connect People Who Need Help to The Help They Need (Connections to Care)</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>3.76 %</i>	<i>D. Address The Needs of Criminal-Justice-Involved Persons</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>0.60 %</i>	<i>E. Address The Needs of Pregnant Or Parenting Women And Their Families, Including Babies With Neonatal Abstinence Syndrome</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>0.23 %</i>	<i>F. Prevent Over-Prescribing and Ensure Appropriate Prescribing and Dispensing Of Opioids</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>8.22 %</i>	<i>G. Prevent Misuse of Opioids</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>2.74 %</i>	<i>H. Prevent Overdose Deaths and Other Harms (Harm Reduction)</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>0.21 %</i>	<i>I. First Responders</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>1.78 %</i>	<i>J. Leadership, Planning and Coordination</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>0.28 %</i>	<i>K. Training</i>	<i>Not Selected</i>	<i>Not Selected</i>
<i>Jan-Jun 2025</i>	<i>0.75 %</i>	<i>L. Research</i>	<i>Not Selected</i>	<i>Not Selected</i>